Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long QT Syndromes.

Moss1

  • 1Heart Research Follow-up Program, Department of Medicine, University of Rochester Medical Center, Box 653, Rochester, NY 14642, USA. heartajm@heart.rochester.edu

Current Treatment Options in Cardiovascular Medicine
|November 30, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancement of HIV Type 1 Antigen-Specific CD4+ T Cell Memory in Subjects with Chronic HIV Type 1 Infection Receiving an HIV Type 1 Immunogen.

AIDS research and human retroviruses·2001
Same author

Comment on "Extreme electrostatic phenomena in a single sonoluminescing bubble"

Physical review letters·2000
Same author

Detecting the onset of bifurcations and their precursors from noisy data

Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics·2000
Same author

Measurement of differences between J/psi and psi(') suppression in p-A collisions

Physical review letters·2000
Same author

Unusually extensive networks of vocal recognition in African elephants.

Animal behaviour·2000
Same author

The bioinformatics resource

Trends in biochemical sciences·2000
Same journal

An Update on the Role of Renal Artery Denervation in the Treatment of Hypertension.

Current treatment options in cardiovascular medicine·2026
Same journal

Advancements and Challenges in Contemporizing Care for Adult Patients with Congenital Heart Disease and Advanced Heart Failure: An Update on Application of Modern Heart Failure Technologies.

Current treatment options in cardiovascular medicine·2026
Same journal

Evolving Decongestion Strategies in the Management of Acute Heart Failure.

Current treatment options in cardiovascular medicine·2025
Same journal

Advanced Electroanatomic Mapping: Current and Emerging Approaches.

Current treatment options in cardiovascular medicine·2025
Same journal

Metabolic Reprogramming in Heart Failure: From Energy Starvation to Therapeutic Targets.

Current treatment options in cardiovascular medicine·2025
Same journal

Drug-Coated Balloons for Coronary Artery Disease: From Theory to Practice.

Current treatment options in cardiovascular medicine·2025
See all related articles

Long QT syndrome (LQTS) management varies, with beta-blockers and ICDs crucial for preventing arrhythmias and sudden cardiac death in high-risk patients.

Area of Science:

  • Cardiology
  • Genetics
  • Pharmacology

Background:

  • Long QT syndrome (LQTS) presents a variable clinical phenotype, with arrhythmia risk influenced by genotype and environmental factors.
  • Malignant ventricular arrhythmias can occur in both symptomatic and previously asymptomatic LQTS patients.

Purpose of the Study:

  • To outline current therapeutic strategies for managing Long QT syndrome (LQTS).
  • To discuss the efficacy and limitations of various treatment modalities for LQTS.

Main Methods:

  • Review of established and emerging treatments for LQTS.
  • Analysis of therapeutic outcomes for beta-adrenergic drugs, pacemakers, ICDs, and surgical interventions.

Main Results:

  • Beta-adrenergic drugs are foundational for symptomatic LQTS patients and prophylactic therapy for asymptomatic individuals.

Related Experiment Videos

  • Beta-blockers reduce syncope but do not eliminate sudden cardiac death risk.
  • Implantable cardioverter-defibrillators (ICDs) serve as effective backup for high-risk patients.
  • Left cervicothoracic sympathetic ganglionectomy is reserved for refractory cases.
  • Gene-specific therapies are in early development.

    • Conclusions:

    • Current LQTS management relies on a combination of pharmacotherapy, device-based interventions, and, in select cases, surgery.
    • While effective, existing treatments have limitations, highlighting the need for further research and personalized therapeutic approaches.